$LLY

Intuitive Surgical posts double-digit growth in 2025 with 12% installed base expansion and 18% surgery increase, unaffected by GLP-1 drug market competition.

Eli Lilly's Omvoh shows durable three-year remission in Crohn's disease, with 92.4% of patients maintaining clinical remission and reduced hospitalizations compared to placebo.

GLP-1 therapeutics market projected to grow from $22B in 2025 to $33B by 2030, driven by formulation innovations like oral and extended-release therapies improving accessibility.

ORBIMED Advisors divested 5.4 million Terns Pharma shares worth $125 million despite the stock's 858% annual gain, reducing its stake as the biotech company advances clinical programs.

Eli Lilly's combo therapy of Taltz and Zepbound showed superior results for psoriasis-obesity patients, achieving 27.1% complete skin clearance versus 5.8% for monotherapy.

Alzheimer's therapeutics market projected to exceed $6B by 2026 driven by rising disease prevalence and increased pharma investment in disease-modifying treatments.

Turner Syndrome treatment market projected to double to $3.67B by 2033, driven by diagnostic innovation, increased awareness, and improved access to therapies globally.

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.

Eli Lilly's Retevmo shows significant benefits in early-stage lung cancer, reducing recurrence risk in Phase 3 trial. Positive results may expand the drug's use beyond advanced-stage disease.

Artios Pharma appoints three senior executives to strengthen manufacturing, clinical operations, and medical affairs as it advances late-stage oncology trials.

Eli Lilly strengthens market position through GLP-1 dominance and strategic acquisitions like Orna Therapeutics, diversifying growth beyond patent cliff risks.

CRISPR Therapeutics reports strong Q4 results with Casgevy gene therapy generating $116M revenue and 147 patient initiations, signaling accelerating adoption and market confidence.

Eli Lilly acquires Orna Therapeutics for $2.4B to gain circular RNA gene therapy technology and autoimmune disease candidates, strengthening its pipeline.

Pfizer's 6.3% dividend yield depends on GLP-1 drug success and managing upcoming patent cliffs as it competes against rivals Novo Nordisk and Eli Lilly in obesity treatments.

Eli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence.